Oruka Therapeutics (NASDAQ:ORKA) Given “Buy” Rating at HC Wainwright

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They presently have a $120.00 target price on the stock. HC Wainwright’s price objective would indicate a potential upside of 40.55% from the company’s current price.

Other equities analysts also recently issued reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Tuesday, April 21st. Wedbush set a $165.00 price objective on Oruka Therapeutics in a research report on Monday, April 27th. Stifel Nicolaus increased their target price on Oruka Therapeutics from $47.00 to $72.00 and gave the company a “buy” rating in a report on Friday, March 13th. Leerink Partners set a $120.00 target price on Oruka Therapeutics in a research report on Thursday, April 30th. Finally, Guggenheim set a $200.00 price target on Oruka Therapeutics and gave the company a “buy” rating in a research note on Monday, April 27th. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $131.30.

Oruka Therapeutics Stock Up 18.0%

Shares of NASDAQ ORKA opened at $85.38 on Tuesday. The company has a market cap of $5.15 billion, a PE ratio of -44.01 and a beta of -0.25. The firm’s 50-day moving average price is $65.16 and its 200-day moving average price is $45.89. Oruka Therapeutics has a 52-week low of $10.77 and a 52-week high of $91.00.

Oruka Therapeutics (NASDAQ:ORKA) last issued its earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.04. As a group, equities research analysts anticipate that Oruka Therapeutics will post -2.06 EPS for the current fiscal year.

Insider Buying and Selling at Oruka Therapeutics

In other news, SVP Arjun Agarwal sold 1,587 shares of the business’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $80.95, for a total transaction of $128,467.65. Following the completion of the sale, the senior vice president owned 15,312 shares of the company’s stock, valued at $1,239,506.40. The trade was a 9.39% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,947 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $69.28, for a total value of $550,568.16. Following the completion of the sale, the insider owned 32,718 shares of the company’s stock, valued at $2,266,703.04. This trade represents a 19.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 185,407 shares of company stock worth $11,636,307. 23.49% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Royal Bank of Canada lifted its position in shares of Oruka Therapeutics by 47.2% during the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after buying an additional 365 shares in the last quarter. Kennedy Capital Management LLC increased its holdings in Oruka Therapeutics by 0.9% in the 4th quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company’s stock worth $1,476,000 after acquiring an additional 420 shares in the last quarter. AlphaCentric Advisors LLC raised its stake in Oruka Therapeutics by 5.8% during the 1st quarter. AlphaCentric Advisors LLC now owns 11,506 shares of the company’s stock worth $564,000 after acquiring an additional 626 shares during the period. Russell Investments Group Ltd. lifted its holdings in Oruka Therapeutics by 35.0% during the fourth quarter. Russell Investments Group Ltd. now owns 3,041 shares of the company’s stock valued at $92,000 after purchasing an additional 788 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Oruka Therapeutics by 62.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,352 shares of the company’s stock worth $71,000 after purchasing an additional 904 shares during the period. Institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development of novel peptide?based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell?permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.